drugset / Trial / NCT07593924
Clinical Trial of PCV13 in Infants Aged Approximately 2 Months (42 to 89 Days)
RandomizedParallel-groupQuadruple-blindPrevention
Summary
A Phase III clinical trial of 13-valent pneumococcal conjugate vaccine (PCV13)developed by Sinovac Life Science Co., Ltd will be conducted in infants aged approximately 2 months (42 to 89 days). The objective of the study is to evaluate the immunogenicity and safety of Sinovac PCV13. The trial is a randomized, double-blind, active controlled phase III clinical trial.
Timeline
- Start
- 2026-05
- Primary completion
- 2027-07
- Completion
- 2027-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Prevnar 13 | Vaccine | 0.5 ml | Intramuscular |
| Subject | Sinovac PCV13 | Vaccine | 0.5 ml | Intramuscular |